Acurx Pharmaceuticals
ACXP
12 hedge funds and large institutions have $1.86M invested in Acurx Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0.34% less ownership
Funds ownership: 0.57% → 0.23% (-0.34%)
14% less funds holding
Funds holding: 14 → 12 (-2)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
65% less capital invested
Capital invested by funds: $5.27M → $1.86M (-$3.41M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$326K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$14.6K |
| 3 |
BlackRock
New York
|
+$1.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$583 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$2.19M |
| 2 |
DAM
Draper Asset Management
Smithtown,
New York
|
-$1.06M |
| 3 |
Millennium Management
New York
|
-$25.7K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$40 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $969K | -$2.19M | -30,000 | -68% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $310K | +$326K | +4,474 | New |
|
3
Geode Capital Management
Boston,
Massachusetts
| $267K | – | – | – |
|
|
4
Millennium Management
New York
| $76K | -$25.7K | -352 | -24% |
|
|
TWC
5
TD Waterhouse Canada
Toronto,
Ontario, Canada
| $63.4K | – | – | – |
|
|
6
BlackRock
New York
| $55.9K | +$1.9K | +26 | +3% |
|
|
7
Osaic Holdings
Scottsdale,
Arizona
| $55.4K | +$14.6K | +200 | +33% |
|
|
TAM
8
Tocqueville Asset Management
New York
| $34.9K | – | – | – |
|
|
BAM
9
Belpointe Asset Management
Reno,
Nevada
| $10.4K | – | – | – |
|
|
10
UBS Group
Zurich,
Switzerland
| $10K | +$583 | +8 | +6% |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $10K | – | – | – |
|
12
Wells Fargo
San Francisco,
California
| $215 | – | – | – |
|
|
DAM
13
Draper Asset Management
Smithtown,
New York
| – | -$1.06M | -13,301 | Closed |
|
|
14
Bank of America
Charlotte,
North Carolina
| – | -$40 | -1 | Closed |
|
ACXP Hedge Fund Activity: Q1 2023 in Review
12 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q1 2023, worth a combined $1.86M — down 65% from $5.27M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ACXP and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, opening a new position worth an estimated $326K. The largest seller was Armistice Capital, cutting an estimated $2.19M.
- 12 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q1 2023, down from 14 in Q4 2022.
- Funds reported $1.86M of Acurx Pharmaceuticals stock for Q1 2023, down 65% quarter-over-quarter.
- 1 fund opened new Acurx Pharmaceuticals positions in Q1 2023 and 2 closed out, a net change of -1 holder.
- The largest Acurx Pharmaceuticals buyer in Q1 2023 was Vanguard Group, an estimated $326K added.
- The largest Acurx Pharmaceuticals seller in Q1 2023 was Armistice Capital, an estimated $2.19M sold.
Based on aggregated 13F filings for Q1 2023.